Targeted Oncology

Scope & Guideline

Advancing cancer care through targeted research.

Introduction

Immerse yourself in the scholarly insights of Targeted Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1776-2596
PublisherSPRINGER
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 2006 to 2024
AbbreviationTARGET ONCOL / Target. Oncol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

Targeted Oncology is dedicated to the exploration and dissemination of cutting-edge research in the field of cancer treatment, specifically focusing on targeted therapies and precision medicine. The journal aims to provide a comprehensive platform for the publication of studies that enhance the understanding of molecular mechanisms of cancer, evaluate the efficacy and safety of novel therapies, and investigate real-world clinical outcomes.
  1. Targeted Therapies in Oncology:
    The journal emphasizes the development and application of targeted therapies, including small molecules, monoclonal antibodies, and antibody-drug conjugates, for various malignancies.
  2. Molecular Characterization of Tumors:
    Research focusing on the molecular and genetic profiling of tumors to identify actionable mutations and guide treatment decisions is a key area of focus.
  3. Real-World Evidence and Outcomes:
    Targeted Oncology publishes studies that provide insights into real-world treatment patterns, patient outcomes, and the effectiveness of therapies in diverse populations.
  4. Clinical Trials and Drug Development:
    The journal includes reports on clinical trials, particularly phase 1 and 2 studies that assess the safety and efficacy of new agents, as well as combination therapies.
  5. Immunotherapy and Combination Approaches:
    Research examining the intersection of immunotherapy with targeted therapies, including immune checkpoint inhibitors and their role in enhancing treatment outcomes.
  6. Emerging Biomarkers and Predictive Models:
    Studies identifying new biomarkers that predict responses to therapy and the development of prognostic models are central to the journal's aims.
Targeted Oncology has seen the emergence of several trending themes reflecting the latest advancements and shifts in cancer research priorities. These themes highlight the journal's commitment to addressing current challenges and innovations in the field.
  1. Integrative Approaches to Precision Medicine:
    There is a growing trend toward integrating genomic, transcriptomic, and proteomic data to develop personalized treatment strategies tailored to individual patients.
  2. Real-World Evidence Studies:
    An increase in real-world evidence studies showcasing treatment effectiveness, patient adherence, and outcomes in routine clinical practice reflects the journal's focus on practical applications of research.
  3. Biomarker-Driven Therapy:
    Emerging research centers on identifying and validating biomarkers that guide therapy selection, particularly in the context of targeted and immunotherapies.
  4. Combination Therapies:
    The exploration of combination therapies that leverage both targeted and immunotherapeutic agents is gaining prominence, underscoring the complexity of cancer treatment.
  5. Patient-Centric Research:
    There is an increased focus on patient-reported outcomes, quality of life studies, and the psychosocial aspects of cancer treatment, reflecting a holistic approach to oncology.

Declining or Waning

As the field of oncology evolves, certain research themes within Targeted Oncology have begun to show a decline in frequency and prominence. These waning scopes reflect shifts in research focus and the introduction of newer methodologies and treatment paradigms.
  1. Traditional Chemotherapy:
    There is a noticeable decline in publications centered around traditional chemotherapy regimens as the focus shifts toward targeted therapies and immunotherapy.
  2. Single-Agent Studies:
    Research exclusively investigating the efficacy of single-agent therapies is less prevalent as combination therapies gain more traction in clinical settings.
  3. General Cancer Epidemiology:
    While still important, broad epidemiological studies without a targeted focus on molecular mechanisms or specific therapies have become less emphasized.
  4. Non-Molecularly Targeted Treatment Strategies:
    The emphasis on non-targeted treatment strategies is decreasing as precision medicine and personalized therapy approaches dominate the landscape.
  5. Basic Science without Clinical Relevance:
    Studies that do not bridge laboratory research with clinical implications are less frequently published, as there is a stronger push for translational research.

Similar Journals

SEMINARS IN ONCOLOGY

Fostering Knowledge Exchange in Oncology Research
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0093-7754Frequency: 6 issues/year

SEMINARS IN ONCOLOGY is a premier journal in the field of oncology, published by W B Saunders Co-Elsevier Inc. With its ISSN 0093-7754 and E-ISSN 1532-8708, this esteemed publication has been contributing significantly to cancer research and education since its inception in 1974. The journal currently holds a distinguished position in the academic landscape, ranking in the Q1 category for Hematology and Q2 for Oncology, and featured prominently in Scopus rankings—34th out of 137 in Medicine Hematology, and 108th out of 404 in Medicine Oncology. SEMINARS IN ONCOLOGY aims to disseminate cutting-edge research, critical reviews, and innovative treatment approaches, making it an invaluable resource for researchers, healthcare professionals, and students dedicated to the fight against cancer. Although not an Open Access journal, it maintains a commitment to high-quality, peer-reviewed content, further solidifying its role as a vital reference point in oncological studies. The journal serves as a crucial platform for the exchange of knowledge, insights, and advancements that shape the future of cancer care.

JTO Clinical and Research Reports

Connecting Researchers and Clinicians for Impactful Discoveries
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

Leukemia Research Reports

Connecting researchers to combat leukemia.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

INVESTIGATIONAL NEW DRUGS

Catalyzing Change in Pharmacological Interventions
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

Clinical Lymphoma Myeloma & Leukemia

Connecting Researchers for a Cure in Hematology
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

CANCER TREATMENT REVIEWS

Bridging research and practice for better patient outcomes.
Publisher: ELSEVIER SCI LTDISSN: 0305-7372Frequency: 10 issues/year

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

CANCER JOURNAL

Empowering Researchers to Combat Cancer Challenges.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

International Journal of Clinical Oncology

Fostering Excellence in Hematology and Oncology
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Nature Reviews Clinical Oncology

Elevating Understanding, Empowering Treatments
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

International Cancer Conference Journal

Innovating Oncology: Insights for a Healthier Tomorrow
Publisher: SPRINGER INT PUBL AGISSN: 2192-3183Frequency: 4 issues/year

International Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.